Therapeutics , Targets , and Chemical Biology High-Throughput Tyrosine Kinase Activity Pro fi ling Identi fi es FAK as a Candidate Therapeutic Target in Ewing Sarcoma

Limited progress has been made in the treatment of advanced-stage pediatric solid tumors despite the accelerated pace of cancer discovery over the last decade. Tyrosine kinase inhibition is one tractable therapeutic modality for treating human malignancy. However, little is known about the kinases critical to the development or maintenance of many pediatric solid tumors such as Ewing sarcoma. Using a fluorescent, bead-based technology to profile activated tyrosine kinases, we identified focal adhesion kinase (FAK, PTK2) as a candidate target in Ewing sarcoma. FAK is a tyrosine kinase critical for cellular adhesion, growth, and survival. As such, it is a compelling target for cancer-based therapy. In this study, we have shown that FAK is highly phosphorylated in primary Ewing sarcoma tumor samples and that downregulation of FAK by short hairpin RNA and treatment with a FAK-selective kinase inhibitor, PF-562271, impaired growth and colony formation in Ewing sarcoma cell lines. Moreover, treatment of Ewing sarcoma cell lines with PF-562271 induced apoptosis and led to downregulation of AKT/mTOR and CAS activity. Finally, we showed that smallmolecule inhibition of FAK attenuated Ewing sarcoma tumor growth in vivo. With FAK inhibitors currently in early-phase clinical trials for adult malignancies, these findings may bear immediate relevance to patients with Ewing sarcoma. Cancer Res; 73(9); 2873–83. 2013 AACR.

[1]  W. Birchmeier,et al.  Targeting MET in cancer: rationale and progress , 2012, Nature Reviews Cancer.

[2]  Kristian Cibulskis,et al.  A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers. , 2012, The Journal of clinical investigation.

[3]  S. Eschrich,et al.  Phosphoproteomics identifies driver tyrosine kinases in sarcoma cell lines and tumors. , 2012, Cancer research.

[4]  D. Camidge,et al.  Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Helen X. Chen,et al.  Insulin Growth Factor-Receptor (IGF-1R) Antibody Cixutumumab Combined with the mTOR Inhibitor Temsirolimus in Patients with Refractory Ewing's Sarcoma Family Tumors , 2012, Clinical Cancer Research.

[6]  J. Xavier-Neto,et al.  Focal adhesion kinase governs cardiac concentric hypertrophic growth by activating the AKT and mTOR pathways. , 2012, Journal of molecular and cellular cardiology.

[7]  D. Reinke,et al.  R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Matthew W. Wilson,et al.  A Novel Retinoblastoma Therapy from Genomic and Epigenetic Analyses , 2011, Nature.

[9]  U. Dirksen,et al.  Risk of recurrence and survival after relapse in patients with Ewing sarcoma , 2011, Pediatric blood & cancer.

[10]  E Wiercinska,et al.  Critical role of endoglin in tumor cell plasticity of Ewing sarcoma and melanoma , 2011, Oncogene.

[11]  P. Sorensen,et al.  Synthetic lethality screens reveal RPS6 and MST1R as modifiers of insulin-like growth factor-1 receptor inhibitor activity in childhood sarcomas. , 2010, Cancer research.

[12]  W. Sellers,et al.  MEK1 mutations confer resistance to MEK and B-RAF inhibition , 2009, Proceedings of the National Academy of Sciences.

[13]  Chiun Hsu,et al.  Overexpressed focal adhesion kinase predicts a higher incidence of extrahepatic metastasis and worse survival in hepatocellular carcinoma. , 2009, Human pathology.

[14]  P. Leavey,et al.  Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Robert E. Brown,et al.  Morphoproteomic confirmation of constitutively activated mTOR, ERK, and NF-kappaB pathways in Ewing family of tumors. , 2009, Annals of clinical and laboratory science.

[16]  Matthew D. Wessel,et al.  Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. , 2008, Cancer research.

[17]  A. Tolcher,et al.  Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M. Basson,et al.  FAK association with multiple signal proteins mediates pressure‐induced colon cancer cell adhesion via a Src‐dependent PI3K/Akt pathway , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[19]  A. Herrero,et al.  Overexpression of Focal Adhesion Kinase in Head and Neck Squamous Cell Carcinoma Is Independent of fak Gene Copy Number , 2006, Clinical Cancer Research.

[20]  A. Martins,et al.  Insulin-Like Growth Factor I Receptor Pathway Inhibition by ADW742, Alone or in Combination with Imatinib, Doxorubicin, or Vincristine, Is a Novel Therapeutic Approach in Ewing Tumor , 2006, Clinical Cancer Research.

[21]  Kazuro Furukawa,et al.  Ganglioside GD3 promotes cell growth and invasion through p130Cas and paxillin in malignant melanoma cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[22]  R. Ophir,et al.  Prediction of high risk Ewing's sarcoma by gene expression profiling , 2004, Oncogene.

[23]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[24]  V. Notario,et al.  Rapamycin induces the fusion-type independent downregulation of the EWS/FLI-1 proteins and inhibits Ewing's sarcoma cell proliferation , 2003, Oncogene.

[25]  M. Tsuneyoshi,et al.  Newly established Askin tumor cell line and overexpression of focal adhesion kinase in Ewing sarcoma family of tumors cell lines. , 2003, Cancer genetics and cytogenetics.

[26]  Francisco Cervantes,et al.  Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. , 2003, The New England journal of medicine.

[27]  G. Nemerow,et al.  Differential regulation of cell motility and invasion by FAK , 2003, The Journal of cell biology.

[28]  S. Donaldson,et al.  Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. , 2003, The New England journal of medicine.

[29]  A. D. Van den Abbeele,et al.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.

[30]  Donna J. Webb,et al.  Urokinase-type Plasminogen Activator Stimulates the Ras/Extracellular Signal-regulated Kinase (ERK) Signaling Pathway and MCF-7 Cell Migration by a Mechanism That Requires Focal Adhesion Kinase, Src, and Shc , 2000, The Journal of Biological Chemistry.

[31]  E. Parkinson,et al.  Increased dosage and amplification of the focal adhesion kinase gene in human cancer cells , 1999, Oncogene.

[32]  J. Guan,et al.  Association of Focal Adhesion Kinase with Grb7 and Its Role in Cell Migration* , 1999, The Journal of Biological Chemistry.

[33]  McDonald,et al.  Nuclear expression of p53, p21 and cyclin D1 is increased in bronchioloalveolar carcinoma , 1999, Histopathology.

[34]  Kenneth M. Yamada,et al.  Tumor suppressor PTEN inhibition of cell invasion, migration, and growth: differential involvement of focal adhesion kinase and p130Cas. , 1999, Cancer research.

[35]  J. Fletcher,et al.  Frequency and implications of chromosome 8 and 12 gains in Ewing sarcoma. , 1998, Cancer genetics and cytogenetics.

[36]  S. Hanks,et al.  Identification of p130Cas as a Mediator of Focal Adhesion Kinase–promoted Cell Migration , 1998, The Journal of cell biology.

[37]  J. Guan,et al.  Phosphorylation of Tyrosine 397 in Focal Adhesion Kinase Is Required for Binding Phosphatidylinositol 3-Kinase* , 1996, The Journal of Biological Chemistry.

[38]  P. Lollini,et al.  Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target. , 1996, Cancer research.

[39]  W. Cance,et al.  Attenuation of the expression of the focal adhesion kinase induces apoptosis in tumor cells. , 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[40]  T. Hunter,et al.  Integrin-mediated signal transduction linked to Ras pathway by GRB2 binding to focal adhesion kinase , 1994, Nature.

[41]  J. Parsons,et al.  Autophosphorylation of the focal adhesion kinase, pp125FAK, directs SH2-dependent binding of pp60src , 1994, Molecular and cellular biology.

[42]  C. Denny,et al.  The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1 , 1993, Molecular and cellular biology.

[43]  J. Parsons,et al.  pp125FAK a structurally distinctive protein-tyrosine kinase associated with focal adhesions. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[44]  C. Beauchamp.  Ewing Sarcoma Demonstrates Racial Disparities in Incidence-related and Sex-related Differences in Outcome: An Analysis of 1631 Cases From the SEER Database, 1973-2005 , 2010 .

[45]  T. Golub,et al.  Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy , 2009, Nature Biotechnology.

[46]  D. A. Hanson,et al.  Focal adhesion kinase: in command and control of cell motility , 2005, Nature Reviews Molecular Cell Biology.

[47]  J. Aguirre Ghiso.  Inhibition of FAK signaling activated by urokinase receptor induces dormancy in human carcinoma cells in vivo , 2002, Oncogene.

[48]  S. Hanks,et al.  Focal adhesion kinase promotes phospholipase C-gamma1 activity. , 1999, Proceedings of the National Academy of Sciences of the United States of America.